Clinical Trials

UK Phase II IMAGO Study

The IMAGO study is a placebo-controlled study to evaluate the safety and efficacy of LUM001 in children with ALGS. The U.K.-based study will enroll children, two years of age and older, with ALGS. Patients that complete the IMAGO will be eligible for participation in a long-term extension study. | For further details on the IMAGO study »
Lumena IMAGO Study

US and Canadian Phase II ITCH Study

The ITCH study is a placebo-controlled study to evaluate the safety and efficacy of LUM001 in children with Alagille syndrome (ALGS). The U.S. and Canadian study will enroll children, two to 18 years of age, with ALGS. Patients that complete the ITCH study will be eligible for participation in a long-term extension study. | For further details on the ITCH study »
Lumena ITCH Study

US, UK and Canadian Phase II IMAGINE Study

The IMAGINE study is a long-term, 48 week extension study to evaluate the safety and efficacy of LUM001 in children with ALGS. The U.S., U.K. and Canadian study will enroll children, two years of age and older, with ALGS. To be eligible, patients must have completed a core treatment protocol of LUM001 in the treatment of cholestatic liver disease in pediatric patients with Alagille Syndrome. | For further details on the IMAGINE study »
Lumena IMAGINE Study